• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Inventiva S.A.

    4/11/25 4:05:40 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IVA alert in real time by email
    6-K 1 tm2511984d1_6k.htm FORM 6-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the Month of April 2025

     

    Commission File Number: 001-39374

     

    Inventiva S.A.

    (Translation of registrant’s name into English)

     

    50 rue de Dijon

    21121 Daix France

    +33 3 80 44 75 00
    (Address of principal executive office)

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

     

    x Form 20-F ¨ Form 40-F

     

     

     

     

     

     

    INCORPORATION BY REFERENCE

     

    The information contained in this report on Form 6-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

     

    INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

     

    Annual General Meeting

     

    On April 11, 2025, Inventiva S.A. published a notice of meeting (the “Notice”) to the Ordinary and Extraordinary General Meeting (the “General Meeting”). The General Meeting will be held on May 22, 2025 at 9 a.m., at Hôtel Villa M, 24-30, boulevard Pasteur – 75015 Paris, France. A copy of the Notice is furnished as Exhibit 99.1 to this Report on Form 6-K.

     

    EXHIBIT INDEX

     

    Exhibit No.   Description
    99.1   Notice of meeting to the Ordinary and Extraordinary General Meeting.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Inventiva S.A.
         
    Date: April 11, 2025 By: /s/ Frédéric Cren
        Name Frédéric Cren
        Title: Chief Executive Officer

     

     

     

    Get the next $IVA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IVA

    DatePrice TargetRatingAnalyst
    2/21/2025$10.00Buy
    TD Cowen
    11/12/2024$3.00Neutral
    UBS
    10/27/2023$12.00Buy
    Canaccord Genuity
    5/31/2023$11.00Buy
    ROTH MKM
    5/19/2023Sell → Buy
    Societe Generale
    3/17/2023$27.00Buy
    Stifel
    11/15/2022Buy → Sell
    Societe Generale
    11/22/2021$40.00 → $42.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $IVA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Inventiva secures the €116 million second tranche of its structured financing of up to €348 million

      Financing follows completion of enrollment of Phase 3 NATiV3 study evaluating lanifibranor in MASH and satisfaction of other specified conditions. Daix (France), New York City (New York, United States), May 5, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and other diseases with significant unmet medical needs, today announced that the Board of Directors called the second tranche of its previously announced1 structured financing of up to €348 million (the "Structured Financi

      5/5/25 2:30:00 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Combined General Meeting of May 22, 2025 - Availability of the preparatory documents

      Daix (France), New York City (New York, United States), April 30,  2025 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), also known as non-alcoholic steatohepatitis ("NASH"), and other diseases with significant unmet medical needs, today announced the availability of the preparatory documents for the Combined General Meeting of May 22, 2025. Shareholders are invited to participate in the Combined General Meeting that will be held on May 22, 2025 at 9 a.m. CEST at Hôtel Villa M, 24 – 30 Boulevard Pasteur, 75015 Par

      4/30/25 4:00:00 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor

      ► Biomarker signatures were developed to predict histological treatment response to lanifibranor treatment in patients with MASH and fibrosis ► The biomarker signatures developed for fibrosis improvement, MASH resolution and composite histological endpoints, suggested better predictive accuracy than other diagnostic scores available including FIB4, FIBC3, ABC3D, NFS, ELF and MACK-3 ► The biomarker signatures suggested strong predictive accuracy, with AUROC values above 0.80 that may indicate high reliability in distinguishing responders from non-responders ► The analysis confirmed that histological response to lanifibranor could be assessed with non-invasive signatures based on blood mark

      4/24/25 4:01:23 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IVA
    SEC Filings

    See more
    • SEC Form 6-K filed by Inventiva S.A.

      6-K - Inventiva S.A. (0001756594) (Filer)

      5/5/25 5:20:28 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Inventiva S.A.

      6-K - Inventiva S.A. (0001756594) (Filer)

      5/2/25 4:05:22 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Inventiva S.A.

      6-K - Inventiva S.A. (0001756594) (Filer)

      4/30/25 4:41:46 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IVA
    Leadership Updates

    Live Leadership Updates

    See more
    • Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million

      Inventiva secures €21.4 million leading to completion of the first tranche of the financing for c. €116 million, part of the multi-tranche equity financing of up to €348 million announced on October 14, 2024.   Proceeds from the completed first tranche to be primarily used to advance Inventiva's Phase III, NATiV3 clinical trial evaluating lanifibranor in patients with MASH.   Appointment of Mark Pruzanski as new Chairman of the Board of Directors and Srinivas Akkaraju as new member of the Board of Directors. Daix (France), New York City (New York, United States), December 16, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinica

      12/16/24 2:30:00 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study

      Inventiva secures €94.1 million of a multi-tranche equity financing of up to €348 million, subject to satisfaction of specified conditions, from both new and existing investors, and up to $30 million in milestone payments relating to equity financing pursuant to amendment to license and collaboration agreement with CTTQ.Proceeds from financing to be primarily used to advance Inventiva's Phase 3, NATiV3 clinical trial evaluating lanifibranor in patients with MASH. More than 1,100 patients randomized in the NATiV3 study evaluating lanifibranor for the treatment of noncirrhotic MASH, with completion of enrollment projected in 1H 2025.Appointment to the Board of Directors of Mark Pruzanski, MD,

      10/14/24 2:30:00 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inventiva announces the nomination of Andre Turenne as Director

      Daix (France), Long Island City (New York, United States), March 28, 2024 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), also known as non-alcoholic steatohepatitis ("NASH") and other diseases with significant unmet medical needs, today announced the nomination of Andre Turenne to its Board of Directors. Mr. Turenne's appointment will be submitted to the shareholders for ratification at the next general shareholder meeting. Frédéric Cren, Chairman, Chief Executive Officer, and cofounder of Inventiva: "We are extre

      3/28/24 3:00:00 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Inventiva S.A.

      SC 13D/A - Inventiva S.A. (0001756594) (Subject)

      10/21/24 9:00:40 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Inventiva S.A.

      SC 13D/A - Inventiva S.A. (0001756594) (Subject)

      10/21/24 8:54:43 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Inventiva S.A.

      SC 13D/A - Inventiva S.A. (0001756594) (Subject)

      7/19/24 4:30:23 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IVA
    Financials

    Live finance-specific insights

    See more
    • Inventiva secures the €116 million second tranche of its structured financing of up to €348 million

      Financing follows completion of enrollment of Phase 3 NATiV3 study evaluating lanifibranor in MASH and satisfaction of other specified conditions. Daix (France), New York City (New York, United States), May 5, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and other diseases with significant unmet medical needs, today announced that the Board of Directors called the second tranche of its previously announced1 structured financing of up to €348 million (the "Structured Financi

      5/5/25 2:30:00 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inventiva reports its 2024 full year results and provides a business update

      Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million Structured Financing closed with aggregate gross proceeds of €116 millionLast patient screened in the NATiV3 Phase 3 clinical trial of lanifibranor in MASH early in January 2025 Pipeline prioritization plan presented to the workers council to focus exclusively on the development of lanifibranor, stopping all preclinical research activities and reducing the workforce by 50% Daix (France), New York City (New York, United States), March 26, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical c

      3/26/25 4:00:00 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results

      Daix (France), New York City (New York, United States), March 19, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company's 2024 full-year financial results on Thursday, March 27, 2025. Inventiva's 2024 full-year financial results will be published on Wednesday, March 26, 2025 at 4:00 pm (New York), 9:00 pm (Paris). Frédéric Cren, CEO and cofounder

      3/19/25 4:00:00 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on Inventiva with a new price target

      TD Cowen initiated coverage of Inventiva with a rating of Buy and set a new price target of $10.00

      2/21/25 8:15:44 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on Inventiva with a new price target

      UBS initiated coverage of Inventiva with a rating of Neutral and set a new price target of $3.00

      11/12/24 7:43:33 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Inventiva with a new price target

      Canaccord Genuity initiated coverage of Inventiva with a rating of Buy and set a new price target of $12.00

      10/27/23 7:43:43 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care